MedTrace Logo

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

NCT02082197 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-06-02

No results posted yet for this study

Summary

This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.

Conditions

  • Hypogonadism
  • Testosterone Deficiency

Interventions

DRUG

ABT-SLV176

ABT-SLV176 administered daily

Sponsors & Collaborators

Principal Investigators

  • Michael Miller, PharmD · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02082197 on ClinicalTrials.gov